Last year was one of the ‘most eventful in US biosimilars history,’ but these analysts say 2022 should be ‘a turning point’

Though last year saw fewer market entrants in the biosimilar space than years past, Cardinal Health still called it one of the “most eventful” in US biosimilars history, acknowledging several key approvals that have the potential to make a big splash.

Sonia Oskouei

“This past year,...

Click to view original post